Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Article
Zimmer, Lisa, Livingstone, Elisabeth, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas, Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kieker, Felix, Dippel, Edgar, Rösch, Alexander, Simon, Jan-Christoph, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C., Schadendorf, Dirk, Berking, Carola, Herbst, Rudolf A., Martens, Uwe M., Sell, Sabine, Stadler, Rudolf, Terheyden, Patrick and Utikal, Jochen (2020) Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 395 (10236), pp. 1558-1568.Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | The Lancet | ||||
| Publisher | Elsevier | ||||
| Place of Publication | NEW YORK | ||||
| Volume | 395 | ||||
| Number of Issue or Book Chapter | 10236 | ||||
| Page Range | pp. 1558-1568 | ||||
| Date | 2020 | ||||
| Date of publication | 11 Oct 2021 12:49 | ||||
| Institutions | Medicine > Lehrstuhl für Dermatologie und Venerologie | ||||
| Identification Number |
| ||||
| Keywords | III MELANOMA; PROLONGED SURVIVAL; IMMUNOTHERAPY; DABRAFENIB; | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 50012 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric